Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Key facts
Counted staff
11
self-reported 11–50 band
Founded
2015
11 years
Legal entities
1
ABR
Office countries
1
1 address
Funding rounds
2
Post IPO equity · Jan 2021 · US$ 17.1M
Company type
Public Company
self-reported
Legal entity
1 brand → 1 confirmed entity
NOXOPHARM LIMITED
ABN50608966123
Legal entities
Show as table · Noxopharm Limited: 1 registry entity
| NOXOPHARM LIMITED | ABN 50608966123 |
|---|---|
| Confirmed matches | 0 of 1 |
A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.
Description
Noxopharm Limited (ASX:NOX) is a clinical-stage Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to improve the safety profile of a wide range of mRNA medicines.
The company utilises specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms – Sofra™ (inflammation, autoimmunity, mRNA drug enhancement, and oncology) and Chroma™ (oncology).
Noxopharm’s management team has extensive and highly relevant experience spanning a wide range of activities, including over 100 years of combined pharma experience, 20+ drug launches in numerous therapeutic areas, involvement in more than 100 clinical trials, 60+ years of academic research and 150+ peer-reviewed publications.
A core strength at all levels of the company is a focus on external collaborations, whether with research institutions and academia, suppliers or industry partners both in Australia and overseas. These relationships enable Noxopharm and its network to efficiently develop new proprietary assets that have demonstrable commercial potential.
Likes and shares are not endorsements
Specialties
All 20 specialties
- RNA
- RIG-I
- inflammatory disease
- oligonucleotides
- mRNA vaccines
- mRNA therapeutics
- autoimmune disease
- TLR7
- TLR8
- TBK1
- preclinical research
- oncology
- drug development
- biotechnology
- nucleic acids
- pharmaceutical
- small molecule
- psoriasis
- lupus
- chronic inflammation
Locations
Country footprint
Show as table · Offices in 1 country
| Countries | 1 |
|---|---|
| Primary country | AU |
All codes: AU
Addresses
- AUSuite 71, 159 Ridgecrop Drive; Sydney - Castle Hill, New South Wales 2154Primary
Grid intelligence Members
Funding
Last round · 3 January 2021US$ 17.1MPost IPO equity
Rounds2
Round typePost IPO equity · secondary transaction
Amount (USD)17,100,000
Stage rank6
Investors named0
Since last round5 yr
Funding
Show as table · 2 funding rounds
| Rounds | 2 |
|---|---|
| Axis | 2015 to 2026 |
| Post IPO equity · 3 Jan 2021 | US$ 17.1M |
Dated rounds only. The axis ends at the date this profile was last observed, not at today.
Signals & hiring
Hiring, headcount and registry-change signals, streamed to members.
Latest signal
Hiring activity
Headcount trend
Financials
Registry-filed capital and financial indicators, standardised by TheGrid.
Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
People & contacts
3 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
Counts only. No names are stored here, and none are served.
FAQ
Which legal entity operates under Noxopharm Limited?
One New South Wales entity on the ABR. NOXOPHARM LIMITED (ABN 50 608 966 123), high confidence.
How many people work at Noxopharm Limited?
The record holds 11 counted staff profiles at January 2026, inside the self-reported 11–50 band.
Where does Noxopharm Limited have offices?
One address on record, Australia only. Primary: Suite 71, 159 Ridgecrop Drive, Sydney - Castle Hill, New South Wales 2154.
Has Noxopharm Limited raised funding?
Two rounds. Latest 3 January 2021: post IPO equity, US$17,100,000.
What does Noxopharm Limited list as its specialties?
20 tags on the brand's own list, among them pharmaceutical, oncology and biotechnology.
Which companies are listed alongside Noxopharm Limited?
13 profiles list Noxopharm Limited as a peer — 87th percentile in Biotechnology Research. It lists ten peers of its own. Myrio Tx and Ternarx list it back.